© 2014, American Society of Nuclear Cardiology. Methods and Results: A study was done of 2,922 consecutive patients (62.9 ± 13 years; 53.4% women) with a normal stress-rest SPECT. The warranty period was defined as the period during which patients remained at a low risk (<1% events/year) of total mortality (TM), or hard events (HE) (cardiac death or non-fatal myocardial infarction). Of these patients, 2,051 were given an exercise myocardial perfusion imaging (Ex-MPI); 461 submaximal exercise plus dipyridamole (Ex+Dipy-MPI); and 410 dipyridamole (Dipy-MPI). During a mean follow-up of 5 ± 3.3 years, a significant reduction (P < .05) of the warranty period for TM (13.5, 9.6 and 8 months) and HE (34.8, 20.5 and 8.2 months) was observed, for Ex-MPI, Ex+Dipy-MPI and Dipy-MPI, respectively. Other warranty period determinants were the clinical variables of age, sex, diabetes and known coronary artery disease. An abnormal left ventricular ejection fraction on gated-SPECT also significantly shortened the warranty period for HE in patients undergoing Ex+Dipy-MPI (P = .001) or Dipy-MPI alone (P = .007).Conclusions: The warranty period for a normal stress-rest SPECT is highly variable since it is primarily determined by the type of stress, the patient’s clinical characteristics and LVEF.Background: To assess different warranty periods following a normal myocardial perfusion SPECT based on patients’ clinical characteristics and the type of stress performed.
- Coronary artery disease
- dipyridamole myocardial perfusion imaging
- exercise myocardial perfusion imaging
- warranty period